Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024

The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is the object of an article published in “Blood Reviews” on 4 September 2024 which examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of drug-drug interactions within the current […]

Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024 Read Post »

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024

The full proceedings of the World Symposium on Pulmonary Hypertension which was held in Barcelona 29.6-1.7, 2024, have now been published in the European Respiratory Journal at this link. The proceedings cover the work of the 15 task forces; Task Force n°1’s article is titled “Exploring the patient perspective in pulmonary hypertension” (see below for

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024 Read Post »

2025 International Society for Heart and Lung Transplant (ISHLT) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Conference, 26 April, 2025

The International CTEPH association (ICA) and International Society for Heart and Lung Transplant (ISHLT) are jointly organising the first CTEPH Conference, held on 26 April 2025 in Boston, USA alongside the ISHLT’s 45th Annual Meeting & Scientific Sessions. Read more at this link

2025 International Society for Heart and Lung Transplant (ISHLT) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Conference, 26 April, 2025 Read Post »

Uniting for Progress: Key Takeaways from the 7th World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024

Six members of the Alliance for Pulmonary Hypertension team—Ioanna Alysandratou, Pisana Ferrari, Mélanie Gallant-Dewavrin, Louise Bouman van der Waal, Hans-Dieter Kulla, and Laure Rosé—attended the 7th World Symposium on Pulmonary Hypertension. The event was both exciting and enriching, offering the privilege of networking with leading medical experts whose innovative work is driving new treatments and

Uniting for Progress: Key Takeaways from the 7th World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024 Read Post »

Hall Skaara reports back from the Pulmonary Hypertension Association conference in Indianapolis, USA, August 15-18, 2024, where he represented PHA Europe

The US Pulmonary Hypertension Association (PHA) hosted its 15th international Pulmonary Hypertension conference in Indianapolis, Indiana, from August 15-18, 2024. This event gathered approximately 1,100 healthcare professionals, researchers, patients, and advocates from across the globe. The event aimed to strengthen connections and promote collaboration within the pulmonary hypertension community. Key sessions included a joint presentation

Hall Skaara reports back from the Pulmonary Hypertension Association conference in Indianapolis, USA, August 15-18, 2024, where he represented PHA Europe Read Post »

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Liquidia Corporation announced on August 20, 2024, that the US Food and Drug Administration (FDA) has granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is supported by the Phase 3 INSPIRE trial, which demonstrated YUTREPIA’s safety and tolerability.

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024

Over the past decade, significant strides have been made in diagnosing and treating pulmonary hypertension, driven by updated criteria and new medications. However, timely diagnosis remains a major challenge, with many patients facing long delays, often waiting years and consulting multiple doctors before receiving an accurate diagnosis. Journalist and healthcare writer Jared Kaltwasser has recently

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024 Read Post »

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024

The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024 Read Post »

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine”

Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine” Read Post »

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has granted orphan drug designation to ZMA001,a first-in-class therapeutic monoclonal antibody designed to control or inhibit inflammation responses in pulmonary blood vessels. ZMA001 could potentially improve both the survival rates and the quality of life of patients by addressing the underlying cause of pulmonary arterial hypertension. The placebo-controlled

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension Read Post »

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024

Selexipag shows promise for treating pulmonary arterial hypertension associated with connective tissue disease (CTD). The ongoing EXPOSURE (EUPAS19085) study sheds light on the real-world management of PAH-CTD patients in Europe and Canada. For more detailed insights, check out the full study results at this link on PubMed Citation Gaine S, Escribano-Subias P, Muller A, Fernandes

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024 Read Post »

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)

The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) Read Post »

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024

Sotatercept, an activin signaling inhibitor, has been recently approved by the FDA for treating pulmonary arterial hypertension (PAH) (see our recent article about the FDA approval at this link), based on two pivotal clinical trials. The authors of the article titled “How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024 Read Post »

The key role of patient associations highlighted during discussions at the 5th French Pulmonary Hypertension Network Meeting, “Respiratory Medicine and Research”, Volume 86, 2024

The 5th French Pulmonary Hypertension Network Meeting, convened in Le Kremlin-Bicêtre, France, in 2023, served as a platform to examine current evidence and outstanding questions in pulmonary hypertension, particularly in the context of the recently published 2022 ESC/ERS Guidelines. The French Network is composed of some of France’s key experts in the field of pulmonary

The key role of patient associations highlighted during discussions at the 5th French Pulmonary Hypertension Network Meeting, “Respiratory Medicine and Research”, Volume 86, 2024 Read Post »

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK

The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK Read Post »

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024

A recent article in “Pulmonary Hypertension News” reports on the tentative approval of Alembic Pharmaceuticals’ generic selexipag as pulmonary arterial hypertension treatment for pulmonary arterial hypertension. Alembic’s generic selexipag contains the same chemical substance as an approved treatment, Uptravi for injection, sold by Johnson & Johnson. Selexipag is a prostacyclin receptor agonist that leads to

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024 Read Post »

Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review

Adherence to medication (MA) is crucial in chronic diseases, but its impact on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) has been less studied. A recent study reviews the adherence patterns, identifies factors linked to low adherence, and examines the associated outcomes in these patients. Methods A systematic review was conducted across

Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review Read Post »

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial

Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial Read Post »

Insights and connections: highlights from the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024

The Alliance for Pulmonary Hypertension team – Ioanna Alysandratou, Pisana Ferrari, Mélanie Gallant-Dewavrin, Louise Bouman – van der Waal, Hans-Dieter Kulla and Laure Rosé – is back from the 7th World Symposium on Pulmonary Hypertension in Barcelona. Attending the World Symposium on Pulmonary Hypertension was an incredibly exciting and enriching experience. The scientific sessions were

Insights and connections: highlights from the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024 Read Post »

Setting the Tone: The Role of Patient Voices at the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024

In his concluding remarks at the 7th World Symposium on Pulmonary Hypertension, Prof. Marc Humbert highlighted the impressive diversity and scale of the event. The symposium hosted 1,697 participants, including 1,102 healthcare professionals, from various specialties, 124 task force members, and 471 industry staff, from over 60 countries. This diversity underscores the global effort and

Setting the Tone: The Role of Patient Voices at the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024 Read Post »

TRANSLATE »
Scroll to Top